Companies and Brands

Rolaids Back on U.S. Store Shelves

Rolaids Intro-Sep13
Source: Courtesy Sanofi
The U.S. division of Paris-based Sanofi (NYSE: SNY) announced on Monday that an iconic U.S. consumer product not named Twinkies is on its way back to store shelves. Over-the-counter antacid Rolaids is once again available after a gap of nearly three years.

Sanofi’s U.S. consumer products subsidiary Chattem Inc. acquired the rights to the Rolaids brand from McNeil-PPC, Inc. — a division of Johnson & Johnson (NYSE: JNJ) — in January of this year and has lived up to its promise to get the product back on store shelves by the end of 2013. J&J pulled Rolaids from the market in December 2010 following the discovery of contamination in the tablets which were made under contract.

J&J reportedly paid $16.6 billion to Pfizer Inc. (NYSE: PFE) to acquire the Rolaids brand in 2006. The terms of the sale to Sanofi was not disclosed.

TV chef Guy Fieri has been hired to market Rolaids and Chattem said it will resurrect one of the most recognizable taglines in advertising history to support the product launch: “How do you spell relief? R-O-L-A-I-D-S.”

Maybe you had to be there.

Shares of Sanofi are up about 0.2% Monday afternoon at $48.08 in a 52-week range of $42.20 to $55.94.

Essential Tips for Investing: Sponsored

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.